Labiotech.eu

News and Trends 14 Feb 2017

Suffering from House Dust Mite Allergy? A New Therapy is on its Way

Allergy Therapeutics, a UK-based biotech company, just announced the approval of its clinical trial application in Spain to advance its next-generation house dust mite allergy vaccine into phase I clinical development. The company Allergy Therapeutics is developing immunotherapeutic vaccines for the treatment of allergies and has been quite successful. Their Pollinex Quattro range of vaccines against […]

February 14, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 14 Feb 2017

Which European Country is Winning the Race in Clinical Development?

A report from the French Association of Biotechnology, France Biotech, could be alerting the French health-care sector this week. The report lists the top European countries leading in clinical development – with France clearly dragging behind other Western European countries. Based on data from the EU Clinical Trials Register, the data compiled by France Biotech reveals which countries are on […]

February 14, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 14 Feb 2017

Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best

GSK announced Phase III results for dolutegravir, which could reduce triple HIV therapy down to two drugs, but Gilead is trying to prove that its candidate bictegravir is better. GSK and Gilead have announced they will present detailed data backing their candidates for a dual HIV therapy. The battlefield will be the Annual Conference on Retroviruses […]

February 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

biotech technology transfer europe researchers

Best in Biotech 14 Feb 2017

10 European Scientists who are the Best at Co-founding Biotech Companies

The “Eureka” moment in the lab is far from the end of a successful story. Whether it’s the recipe for the next wonder therapy or a means of independence from fossil fuels, creating a company and making scientific discoveries to commercial reality is hard. We take a look at the best at translating research from the bench […]

February 14, 2017 - 6 minutesmins - By Denise Neves Gameiro

News and Trends 13 Feb 2017

Biotech from the Bermuda Islands Brings Good News for Dementia Patients

Axovant Sciences has announced positive preliminary results from a Phase II trial directed at reducing hallucinations in patients with dementia. Axovant Sciences is a biotech located in Bermuda, a British tropical island in the Atlantic ocean. From there, the company develops drugs against dementia. The company was founded by young biotech entrepreneur Vivek Ramaswamy, which has […]

February 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Acacia Pharma Phase III Post Operative Nausea

More News! 13 Feb 2017

To the Rescue: A Final Phase III Success for Post-Operative Nausea

The dopamine antagonist Baremsis is on its way to FDA approval for the treatment and prophylaxis of post-operative nausea & vomiting, after succeeding in a final phase III study. Acacia Pharma, one of our Cambridge top 15 biotechs, is repurposing marketed drugs to provide supportive treatments for post-surgical or cancer patients. Their lead project, Baremsis, is a dopamine antagonist, which Acacia is […]

February 13, 2017 - 3 minutesmins - By Melanie De Almeida

Infographics 13 Feb 2017

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up? Since the dawn of immuno-oncology broke with checkpoint inhibitors, innovative therapies like Keytruda and Rituxan from big pharma have taken the world by storm. European biotech’s pipeline is […]

February 13, 2017 - 2 minutesmins - By Evelyn Warner

More News! 11 Feb 2017

This Musician Plays Piano Duets with a Microorganism

Eduardo Miranda researches, composes and performs contemporary music at the interface of biology, computing and the human mind. Eduardo Miranda, Professor of Computer Music at Plymouth University, is the first person to ever compose and perform a piano piece for a human and a microorganism. To allow the tiny creature to play with him, Miranda […]

February 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Feb 2017

Germany gains Strength in Allergy Immunotherapeutics

Bencard Allergie is developing ultra-short course allergy immunotherapies, backed by a strong growth in its German market. Bencard Allergie is the German subsidiary of Allergy Therapeutics in the UK, which develops allergy vaccines. The German company was the first to market allergoids for allergen-specific immunotherapies. These are proteins modified to be recognized by immune cells while inducing […]

February 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Feb 2017

A Dutch University Hospital has Halted Amyloid Beta Drug Studies

Despite the popularity of amyloid beta-targeting drugs, none have managed to pass late stage clinical trials, prompting UMC Radboud to halt its own studies. In the latest blow to the amyloid beta hypothesis, Radboud University Medical Centre in Nijmegen, the Netherlands, announced that it will no longer continue studies into drugs targeting misfolded amyloid beta. These […]

February 10, 2017 - 3 minutesmins - By Diana Kwon

antivenom shortage biotechnology antibody

News and Trends 10 Feb 2017

Can Biotech make Antivenoms Better and Cheaper with Antibodies?

Recombinant antibodies have yet to be applied to the treatment of snakebites, a neglected tropical ‘disease.’ Researchers from Denmark investigated the technology and cost of this novel approach in biotech. Bites from venomous snakes are a major public health problem in tropical areas, where 2 to 3 million people are affected every year and an estimated 100,000 […]

February 10, 2017 - 3 minutesmins - By Denise Neves Gameiro

More News! 9 Feb 2017

After its First Success, the Virtual Biotech Team is Back at it Again

SuperX has raised €10.3M ($11M) in Series A from Medicxi and J&J Innovation to develop anticoagulant antibodies for stroke and heart attacks. The team behind XO1, which was acquired by J&J’s Janssen back in 2015, is repeating the whole process again. Their new company, SuperX, is also focused on the discovery of anticoagulant antibodies to treat […]

February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Suffering from House Dust Mite Allergy? A New Therapy is on its Way

Which European Country is Winning the Race in Clinical Development?

Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best

10 European Scientists who are the Best at Co-founding Biotech Companies

Biotech from the Bermuda Islands Brings Good News for Dementia Patients

To the Rescue: A Final Phase III Success for Post-Operative Nausea

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

This Musician Plays Piano Duets with a Microorganism

Germany gains Strength in Allergy Immunotherapeutics

A Dutch University Hospital has Halted Amyloid Beta Drug Studies

Can Biotech make Antivenoms Better and Cheaper with Antibodies?

After its First Success, the Virtual Biotech Team is Back at it Again

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!